cholesterol news from FierceBiotech
NewsMerck shelves study of cholesterol drug
Saying it had the wrong patient population, Merck has discontinued its ACHIEVE imaging study for its cholesterol drug MK-0524A. Its steering committee recommended a new imaging study that included a Read more...
Analyst predicts a long delay for Merck's Cordaptive
There's more bad news--or analysis--for Merck's drug development efforts. After the FDA Read more...
Esperion gets second shot as an independent drugmaker
After getting squashed in Pfizer's restructuring crunch, Esperion Therapeutics is reopening this week. The company, which specializes in cardiovascular and metabolic disease work, is hiring about 10 Read more...
Cholesterol drug delay signals new FDA standards
In what may signal a major shift in FDA standards, Isis and Genzyme say that they expect to add another year to the development timeline for a closely watched cholesterol therapy in order to produce Read more...
SPOTLIGHT: Merck halts trial enrollment
Merck's giant migraine over the Vytorin data is spilling into one of its development programs. Researchers halted enrollment in a late-stage study of the cholesterol drug Cordaptive to ponder Read more...
Merck scores high in race for cholesterol drug
Merck is reporting success in its Phase III trial of a new cholesterol drug that combines a known ingredient with a new one that reduces the risk of an uncomfortable and common side effect. Read more...
AstraZeneca, Abbott plan combo pill
Abbott and AstraZeneca are planning to Phase III trial a pill combining two drugs to target all three major blood lipids--LDL-C "bad" cholesterol, HDL-C "good" cholesterol, and Read more...
| Press ReleasesPRESS RELEASE: Merck's "Good" Cholesterol Drug Meets Trial Goals Merck's "Good" Cholesterol Drug Meets Trial Goals WHITEHOUSE STATION, N.J.--Merck & Co., Inc. announced today Phase III clinical study results with CORDAPTIVE(TM) (ER niacin/ Read more... PRESS RELEASE: Merck Announces FDA Acceptance of NDA for CORDAPTIVE Merck Announces FDA Acceptance of NDA for CORDAPTIVE (ER niacin/laropiprant), Formerly Known as MK-0524A, an Investigational Lipid-Modifier WHITEHOUSE STATION, N.J. -- Merck & Co., Inc. Read more... |
Get more cholesterol coverage at:
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends